We Truly Care About Your Health
We Truly Care About Your Health
Tasly has the world’s largest proprietary automatic dripping pill and outer package production line, which meets international standards, including global online control and online inspection of key process parameters. This production line features industry-leading intensive web-based control, online diagnosis, high-speed operation, precision pill counting, label attachment, automatic online imprint monitoring, and automated incompliant product detection and removal. The entire line, which is controlled by computers and digitally operated with convenient and vivid parameter adjustment, may run automatically from feeding to finished product collection without any manual intervention.
By 2003 Tasly has obtained certifications in respect of ISO 9001/ISO 14001/OHSAS 18001, IP Multimedia Subsystem, ISO 10012 (quality measurement management), GMP for ingredient extraction and TGA of Australia, achieving normalized management, formalized technical implementation, streamlined process control and standardized quality assessment for herbal ingredient extraction to the extent of complete safety of the product’s active ingredients.
The innovative high-speed new dripping pill machine made by Tasly, the first capable of performing global automatic control, including real-time monitoring of parameters on heating, temperature, solid content and charomatographic fingerprinting, pioneers in practical application of PAT (Process Analytical Technology) in TCM production; the state-of-the-art ultra-high-speed oscillatory dripping and gas condensation technology complies with FDA criteria and EU cGMP and realizes complete compatibility of modernized TCM manufacture with popular international drug making standards.
Tianjin Tasly Saint Pharmaceutical Co., Ltd, a joint venture incorporated Oct. 30, 2007 by Tasly Group and Britain’s Co-operative Group with total investments of $50 million, resides in Beichen Science Park, Tianjin, occupies an area of 33,000m2 and has a plant of 24,000m2 in floor area. The JV, which is now registered as Tianjin Tasly Saint Pharmaceutical Co., Ltd, will be renamed Tasly Co-operative (Tianjin) Pharmaceutical Co., Ltd.
The company focuses its business on drug research, development and manufacturing and is expected to make 2.1 billion solid tablets per annum, which are all exported to Europe. Designed in compliance with GMP standards set by EU, MHRA and FDA, the plant is China’s first pharmaceutical enterprise accredited by the three international drug regulatory agencies. All manufacturing facilities and lab appliances are outsourced from world-class suppliers for flexible production arrangement and conformity with different market requirements.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd, residing beside the ancient Grand Canal in Huai’an, Jiangsu province, a historically and culturally famous city and hometown of China’s distinguished first Premier Zhou Enlai, is a subsidiary held by Tasly Group and a modernized pharmaceutical enterprise engaging in the R&D, manufacturing and marketing of medicinal products.
Positioned to be the base of Tianjin Tasly Group for pharmaceutical chemicals, the company gives priority to anticancer drugs and combination drugs with anticancer ingredients included. Situated at 29 Chengnan Xi Lu, Huai’ai, Jiangsu province and occupying an area of 165,000m2, the company specializes in APIs and oral solid preparations and carries a product line of anticancer drugs, cardiovascular drugs, mental illness-related drugs and medications for hepatic protection.
APIs: 13 products including glucuronolactone, flutamide, temozolomide, silybin and bezafibrate. The company is now the world’s largest glucuronolactone manufacturer with an annual capacity of 600 tons and annual export of 500 tons.
Oral solid formulations: tablets and capsules with an annual capacity of 1.6 billion; products: more than 80 including Diqing (Temozolomide Capsules), class-ii new drug for glioblastoma multiforme, Flutamide (tablet & capsule in dosage form), class-ii new drug for prostate cancer, Diyiluo (Lisinopril capsule), class-iv new drug for hypertension, and Weifei (eszopiclone), class-ii new drug for various types of insomnia.